Amedeo Smart

Free Medical Literature Service


 

Amedeo

Breast Cancer

  Free Subscription

Articles published in
Clin Cancer Res
    November 2017
  1. AUSHEV VN, Lee E, Zhu J, Gopalakrishnan K, et al
    Novel predictors of breast cancer survival derived from miRNA activity analysis.
    Clin Cancer Res. 2017 Nov 14. pii: clincanres.0996.2017.
    >> Share

  2. EVANS KW, Yuca E, Akcakanat A, Scott SM, et al
    A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.
    Clin Cancer Res. 2017;23:6468-6477.
    >> Share

    October 2017
  3. HSU PY, Wu VS, Kanaya N, Petrossian K, et al
    Dual mTOR Kinases MLN0128 Inhibitor Sensitizes HR+/HER2+ Breast Cancer Patient-derived Xenografts to Trastuzumab or Fulvestrant.
    Clin Cancer Res. 2017 Oct 27. pii: clincanres.1983.2017.
    >> Share

  4. PRICEMAN SJ, Tilakawardane D, Jeang B, Murad JP, et al
    Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain.
    Clin Cancer Res. 2017 Oct 23. pii: clincanres.2041.2017.
    >> Share

  5. YU Z, He S, Wang D, Patel HK, et al
    Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor Positive Breast Cancer Models with a Distinct Mechanism of Action.
    Clin Cancer Res. 2017 Oct 3. pii: clincanres.0670.2017.
    >> Share

    September 2017
  6. LUNDBERG A, Lindstrom LS, Harrell JC, Falato C, et al
    Gene expression signatures and immunohistochemical subtypes add prognostic value to each other in breast cancer cohorts.
    Clin Cancer Res. 2017 Sep 29. pii: clincanres.1535.2017.
    >> Share

  7. TOBIN NP, Lundberg A, Lindstrom LS, Harrell JC, et al
    PAM50 provides prognostic information when applied to the lymph node metastases of advanced breast cancer patients.
    Clin Cancer Res. 2017 Sep 29. pii: clincanres.2301.2017.
    >> Share

  8. DOOSTAN I, Karakas C, Kohansal M, Low KH, et al
    Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer.
    Clin Cancer Res. 2017 Sep 25. pii: clincanres.1544.2017.
    >> Share

  9. ZHANG Y, Schroeder BE, Jerevall PL, Ly A, et al
    A novel Breast Cancer Index for prediction of distant recurrence in HR+ early stage breast cancer with 1 to 3 positive nodes.
    Clin Cancer Res. 2017 Sep 22. pii: clincanres.1688.2017.
    >> Share

  10. DIOT G, Metz S, Noske A, Liapis E, et al
    Multi-Spectral Optoacoustic Tomography (MSOT) of human breast cancer.
    Clin Cancer Res. 2017 Sep 12. pii: clincanres.3200.2016.
    >> Share

  11. MA CX, Suman V, Goetz MP, Northfelt DW, et al
    A Phase II trial of neoadjuvant MK2206, an AKT inhibitor, with anastrozole in clinical stage 2 or 3 PIK3CA mutant ER positive and HER2 negative breast cancer.
    Clin Cancer Res. 2017 Sep 5. pii: clincanres.1260.2017.
    >> Share

    August 2017
  12. SABBAGHI M, Gil-Gomez G, Guardia C, Servitja S, et al
    Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer.
    Clin Cancer Res. 2017 Aug 18. pii: clincanres.0696.2017.
    >> Share

  13. EMENS LA
    Breast Cancer Immunotherapy: Facts and Hopes.
    Clin Cancer Res. 2017 Aug 11. pii: clincanres.3001.2017.
    >> Share

  14. VAN DER VELDEN BHM, Elias SG, Bismeijer T, Loo CE, et al
    Complementary value of contralateral parenchymal enhancement on DCE-MRI to prognostic models and molecular assays in high-risk ER+HER2- breast cancer.
    Clin Cancer Res. 2017 Aug 8. pii: clincanres.0176.2017.
    >> Share

    July 2017
  15. FORMISANO L, Stauffer KM, Young CD, Bhola NE, et al
    Association of FGFR1 with ERalphamaintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER+ breast cancer.
    Clin Cancer Res. 2017 Jul 27. pii: clincanres.1232.2017.
    >> Share

  16. SUN J, Meng H, Yao L, Lv M, et al
    Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients.
    Clin Cancer Res. 2017 Jul 19. pii: clincanres.3227.2016.
    >> Share

  17. UEDA S, Saeki T, Osaki A, Yamane T, et al
    Bevacizumab induces acute hypoxia and cancer progression in patients with refractory breast cancer: Multimodal functional imaging and multiplex cytokine analysis.
    Clin Cancer Res. 2017 Jul 5. pii: clincanres.0874.2017.
    >> Share

  18. RIETHDORF S, Muller V, Loibl S, Nekljudova V, et al
    Prognostic impact of circulating tumor cells for breast cancer patients treated in the neoadjuvant "Geparquattro" trial.
    Clin Cancer Res. 2017 Jul 5. pii: clincanres.0255.2017.
    >> Share

  19. MA CX, Bose R, Gao F, Freedman RA, et al
    Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Non-amplified Metastatic Breast Cancer.
    Clin Cancer Res. 2017 Jul 5. pii: clincanres.0900.2017.
    >> Share

    June 2017
  20. KENNY T, Schmidt H, Adelson K, Hoshida Y, et al
    Patient-derived interstitial fluids and predisposition to aggressive sporadic breast cancer through collagen remodeling and inactivation of p53.
    Clin Cancer Res. 2017 Jun 19. pii: clincanres.0342.2017.
    >> Share

  21. TURNER NC, Asghar U, Barr AR, Cutts R, et al
    Single-cell dynamics determines response to CDK4/6 inhibition in triple negative breast cancer.
    Clin Cancer Res. 2017 Jun 12. pii: clincanres.0369.2017.
    >> Share

  22. REEDER-HAYES KE, Anderson BO
    Breast Cancer Disparities at Home and Abroad: A Review of the Challenges and Opportunities for System-Level Change.
    Clin Cancer Res. 2017;23:2655-2664.
    >> Share

  23. FREEDMAN RA, Partridge AH
    Emerging Data and Current Challenges for Young, Old, Obese, or Male Patients with Breast Cancer.
    Clin Cancer Res. 2017;23:2647-2654.
    >> Share

  24. VONDERHEIDE RH, Domchek SM, Clark AS
    Immunotherapy for Breast Cancer: What Are We Missing?
    Clin Cancer Res. 2017;23:2640-2646.
    >> Share

  25. YATES LR, Desmedt C
    Translational Genomics: Practical Applications of the Genomic Revolution in Breast Cancer.
    Clin Cancer Res. 2017;23:2630-2639.
    >> Share

  26. NIK-ZAINAL S, Morganella S
    Mutational Signatures in Breast Cancer: The Problem at the DNA Level.
    Clin Cancer Res. 2017;23:2617-2629.
    >> Share

  27. PARTRIDGE AH, Carey LA
    Unmet Needs in Clinical Research in Breast Cancer: Where Do We Need to Go?
    Clin Cancer Res. 2017;23:2611-2616.
    >> Share

    May 2017
  28. SCHOTT AF, Goldstein L, Cristofanilli M, Ruffini PA, et al
    Phase Ib pilot study to evaluate reparixin in combination with weekly paclitaxel in patients with HER-2 negative metastatic breast cancer (MBC).
    Clin Cancer Res. 2017 May 24. pii: clincanres.2748.2016.
    >> Share

  29. REINHOLZ MM, Chen B, Dueck AC, Tenner K, et al
    IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831.
    Clin Cancer Res. 2017 May 22. doi: 10.1158/1078-0432.CCR-15-0574.
    >> Share

  30. DICKLER MN, Tolaney S, Rugo HS, Cortes J, et al
    MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer.
    Clin Cancer Res. 2017 May 22. pii: clincanres.0754.2017.
    >> Share

  31. SHAASHUA L, Shabat-Simon M, Haldar R, Matzner P, et al
    Perioperative COX-2 and β-adrenergic blockade improves metastatic biomarkers in breast cancer patients in a phase-II randomized trial.
    Clin Cancer Res. 2017 May 10. pii: clincanres.0152.2017.
    >> Share

  32. SILWAL-PANDIT L, Nord S, von der Lippe Gythfeldt H, Moller EK, et al
    The longitudinal transcriptional response to neoadjuvant chemotherapy with and without bevacizumab in breast cancer.
    Clin Cancer Res. 2017 May 9. pii: clincanres.0160.2017.
    >> Share

  33. XU X, De Angelis C, Burke KA, Nardone A, et al
    HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.
    Clin Cancer Res. 2017 May 9. pii: clincanres.2191.2016.
    >> Share

  34. BIHANI T, Patel HK, Arlt H, Tao N, et al
    Elacestrant (RAD1901), a selective estrogen receptor degrader (SERD), has anti-tumor activity in multiple ER+ breast cancer patient-derived xenograft models.
    Clin Cancer Res. 2017 May 4. pii: clincanres.2561.2016.
    >> Share

  35. TORRES-ADORNO AM, Lee J, Kogawa T, Ordentlich P, et al
    Histone deacetylase inhibitor enhances the efficacy of MEK inhibitor through NOXA-mediated MCL1 degradation in triple-negative and inflammatory breast cancer.
    Clin Cancer Res. 2017 May 2. pii: clincanres.2622.2016.
    >> Share

    April 2017
  36. PIEROBON M, Ramos C, Wong S, Hodge KA, et al
    Enrichment of PIK3-AKT-MTOR pathway activation in hepatic metastases from breast cancer.
    Clin Cancer Res. 2017 Apr 26. pii: clincanres.2656.2016.
    >> Share

  37. WEERTS MJA, Hollestelle A, Sieuwerts AM, Foekens JA, et al
    Low Tumor Mitochondrial DNA Content is Associated with Better Outcome in Breast Cancer Patients Receiving Anthracycline-based Chemotherapy.
    Clin Cancer Res. 2017 Apr 18. pii: clincanres.0032.2017.
    >> Share

  38. ASSADIPOUR Y, Zacharakis N, Crystal JS, Prickett TD, et al
    Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple Negative Breast Cancer.
    Clin Cancer Res. 2017 Apr 4. pii: clincanres.1423.2016.
    >> Share

    March 2017
  39. SOMLO G, Frankel P, Arun B, Ma CX, et al
    Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer.
    Clin Cancer Res. 2017 Mar 29. pii: clincanres.2714.2016.
    >> Share

  40. PITRODA S, Bao R, Andrade J, Weichselbaum RR, et al
    Low Recombination Proficiency Score (RPS) predicts heightened sensitivity to DNA-damaging chemotherapy in breast cancer.
    Clin Cancer Res. 2017 Mar 24. pii: clincanres.2845.2016.
    >> Share

  41. LEE H, Shields AF, Siegel BA, Miller KD, et al
    64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer.
    Clin Cancer Res. 2017 Mar 15. pii: clincanres.3193.2016.
    >> Share

  42. SCHWARTZBERG LS, Yardley D, Elias A, Patel M, et al
    A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer.
    Clin Cancer Res. 2017 Mar 9. pii: clincanres.2339.2016.
    >> Share

  43. JOVANOVIC B, Mayer IA, Mayer EL, Abramson VG, et al
    A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus in patients with stage II/III triple-negative breast cancer (TNBC).
    Clin Cancer Res. 2017 Mar 7. pii: clincanres.3055.2016.
    >> Share

  44. MA CX, Gao F, Luo J, Northfelt DW, et al
    NeoPalAna: Neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor positive breast cancer.
    Clin Cancer Res. 2017 Mar 7. pii: clincanres.3206.2016.
    >> Share

    February 2017
  45. HUSING A, Fortner RT, Kuhn T, Overvad K, et al
    Added value of serum hormone measurements in risk prediction models for breast cancer for women not using exogenous hormones: Results from the EPIC cohort.
    Clin Cancer Res. 2017 Feb 28. pii: clincanres.3011.2016.
    >> Share

    January 2017
  46. SHACHAR SS, Deal AM, Weinberg M, Williams GR, et al
    Body Composition as a Predictor of Toxicity in Patients Receiving Anthracycline and Taxane Based Chemotherapy for Early Stage Breast Cancer.
    Clin Cancer Res. 2017 Jan 31. pii: clincanres.2266.2016.
    >> Share

  47. SINGER CF, Tan YY, Fitzal F, Steger GG, et al
    Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer.
    Clin Cancer Res. 2017 Jan 31. pii: clincanres.2373.2016.
    >> Share

  48. DEGNIM AC, Hoskin TL, Arshad M, Frost MH, et al
    Alterations in the Immune Cell Composition in Premalignant Breast Tissue that Precede Breast Cancer Development.
    Clin Cancer Res. 2017 Jan 26. pii: clincanres.2026.2016.
    >> Share


  49. Retraction: Effective Targeting of Triple-Negative Breast Cancer Cells by PF-4942847, a Novel Oral Inhibitor of Hsp 90.
    Clin Cancer Res. 2017;23:612.
    >> Share

  50. AFGHAHI A, Timms KM, Vinayak S, Jensen KC, et al
    Tumor BRCA1 Reversion Mutation Arising During Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance.
    Clin Cancer Res. 2017 Jan 13. pii: clincanres.2174.2016.
    >> Share

  51. HART CD, Vignoli A, Tenori L, Uy GL, et al
    Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population.
    Clin Cancer Res. 2017 Jan 12. doi: 10.1158/1078-0432.CCR-16-1153.
    >> Share

  52. WU J, Cui Y, Sun X, Cao G, et al
    Unsupervised clustering of quantitative image phenotypes reveals breast cancer subtypes with distinct prognoses and molecular pathways.
    Clin Cancer Res. 2017 Jan 10. pii: clincanres.2415.2016.
    >> Share

  53. CARDILLO TM, Sharkey RM, Rossi DL, Arrojo R, et al
    Synthetic lethality exploitation by an anti-Trop-2-SN-38 antibody-drug conjugate, IMMU-132, plus PARP-inhibitors in BRCA1/2-wild-type triple-negative breast cancer.
    Clin Cancer Res. 2017 Jan 9. pii: clincanres.2401.2016.
    >> Share

  54. MOULDER-THOMPSON S, Borges VF, Baetz TD, Mcspadden T, et al
    Phase 1 Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+ Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC).
    Clin Cancer Res. 2017 Jan 4. pii: clincanres.1496.2016.
    >> Share

    December 2016
  55. LIU Y, Burness ML, Martin-Trevino R, Guy J, et al
    RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.
    Clin Cancer Res. 2016 Dec 29. doi: 10.1158/1078-0432.CCR-15-1348.
    >> Share

  56. HUMPHRIES MP, Sundara Rajan S, Droop A, Suleman C, et al
    A Case Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic and Tractable Biomarkers in Male Breast Cancer.
    Clin Cancer Res. 2016 Dec 16. pii: clincanres.1952.2016.
    >> Share

  57. CONNOLLY R, Li H, Jankowitz RC, Zhang Z, et al
    Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study.
    Clin Cancer Res. 2016 Dec 15. pii: clincanres.1729.2016.
    >> Share

  58. JANKOWITZ RC, Oesterreich S, Lee AV, Davidson NE, et al
    New Strategies in Metastatic Hormone Receptor-Positive Breast Cancer: Searching for Biomarkers to Tailor Endocrine and other Targeted Therapies.
    Clin Cancer Res. 2016 Dec 15. pii: clincanres.0591.2016.
    >> Share

  59. LECONET W, Chentouf M, Du Manoir S, Chevalier C, et al
    Therapeutic activity of anti-AXL antibody against triple-negative breast cancer Patient Derived Xenografts and metastasis.
    Clin Cancer Res. 2016 Dec 6. pii: clincanres.1316.2016.
    >> Share

    November 2016
  60. HOSFORD SR, Dillon LM, Bouley SJ, Rosati R, et al
    Combined inhibition of both p110alpha and p110beta isoforms of phosphatidylinositol 3-kinase is required for sustained therapeutic effect in PTEN-deficient, ER+ breast cancer.
    Clin Cancer Res. 2016 Nov 30. pii: clincanres.2764.2015.
    >> Share

  61. PRAT A, Lluch A, Turnbull AK, Dunbier AK, et al
    A PAM50-based Chemo-Endocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse.
    Clin Cancer Res. 2016 Nov 30. pii: clincanres.2092.2016.
    >> Share

  62. HUNT KK, Karakas C, Ha MJ, Biernacka A, et al
    Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer.
    Clin Cancer Res. 2016 Nov 23. pii: clincanres.2217.2016.
    >> Share

  63. LAMBERTS LE, Koch M, de Jong JS, Adams A, et al
    Tumor-specific uptake of fluorescent bevacizumab-IRDye800CW microdosing in patients with primary breast cancer: a phase I feasibility study.
    Clin Cancer Res. 2016 Nov 9. pii: clincanres.0437.2016.
    >> Share

  64. BOZOVIC-SPASOJEVIC I, Zardavas D, Brohee S, Ameye L, et al
    The prognostic role of androgen receptor in patients with early stage breast cancer: A meta-analysis of clinical and gene expression data.
    Clin Cancer Res. 2016 Nov 9. pii: clincanres.0979.2016.
    >> Share

  65. ELEBRO K, Borgquist S, Rosendahl AH, Markkula A, et al
    High estrogen receptor beta expression is prognostic among adjuvant chemotherapy-treated patients - results from a population-based breast cancer cohort.
    Clin Cancer Res. 2016 Nov 3. pii: clincanres.1095.2016.
    >> Share

  66. BRAND JS, Hedayati E, Humphreys K, Ludvigsson JF, et al
    Chemotherapy, Genetic Susceptibility, and Risk of Venous Thromboembolism in Breast Cancer Patients.
    Clin Cancer Res. 2016;22:5249-5255.
    >> Share

    October 2016
  67. CHAN N, Willis A, Kornhauser N, Ward MM, et al
    Influencing the tumor microenvironment: Phase 2 Study of Copper depletion with tetrathiomolybdate in high risk breast cancer and preclinical models of lung metastases.
    Clin Cancer Res. 2016 Oct 21. pii: clincanres.1326.2016.
    >> Share

  68. ZEMBUTSU H, Nakamura S, Akashi ST, Kuwayama T, et al
    Significant Effect of Polymorphisms in CYP2D6 on Response to Tamoxifen Therapy for Breast Cancer; a Prospective Multicenter Study.
    Clin Cancer Res. 2016 Oct 19. pii: clincanres.1779.2016.
    >> Share

  69. BRECHBUHL HM, Finlay-Schultz J, Yamamoto T, Gillen A, et al
    Fibroblast subtypes regulate responsiveness of luminal breast cancer to estrogen.
    Clin Cancer Res. 2016 Oct 4. pii: clincanres.2851.2015.
    >> Share

  70. MERCOGLIANO MF, De Martino M, Venturutti L, Rivas MA, et al
    TNFalpha-induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
    Clin Cancer Res. 2016 Oct 3. pii: clincanres.0970.2016.
    >> Share

  71. ZUO WJ, Jiang YZ, Wang YJ, Xu XE, et al
    Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer.
    Clin Cancer Res. 2016;22:4859-4869.
    >> Share

    September 2016
  72. RENNERT G, Pinchev M, Gronich N, Saliba W, et al
    Oral bisphosphonates and improved survival of breast cancer.
    Clin Cancer Res. 2016 Sep 28. pii: clincanres.0547.2016.
    >> Share


  73. Correction: Novel Antitumor Effect of Estradiol in Athymic Mice Injected with a T47D Breast Cancer Cell Line Overexpressing Protein Kinase C Alpha.
    Clin Cancer Res. 2016;22:4756.
    >> Share

  74. LIPS EH, Debipersad R, Scheerman CE, Mulder L, et al
    BRCA1-mutated estrogen receptor positive breast cancer shows BRCAness, suggesting sensitivity to drugs targeting homologous recombination deficiency.
    Clin Cancer Res. 2016 Sep 12. pii: clincanres.0198.2016.
    >> Share

  75. NIELSEN TO, Jensen MB, Burugu S, Gao D, et al
    High risk premenopausal Luminal A breast cancer patients derive no benefit from adjuvant cyclophosphamide-based chemotherapy: results from the DBCG77B clinical trial.
    Clin Cancer Res. 2016 Sep 6. pii: clincanres.1278.2016.
    >> Share

  76. VON WAHLDE MK, Timms KM, Chagpar AB, Wali VB, et al
    Intratumor heterogeneity of homologous recombination deficiency in primary breast cancer.
    Clin Cancer Res. 2016 Sep 6. pii: clincanres.0889.2016.
    >> Share


  77. Correction: Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70).
    Clin Cancer Res. 2016;22:4536.
    >> Share

  78. QUINTELA-FANDINO M, Lluch A, Manso LM, Calvo I, et al
    18F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-negative breast cancer: a window-of-opportunity randomized trial.
    Clin Cancer Res. 2016 Sep 1. pii: clincanres.0738.2016.
    >> Share

    August 2016
  79. MCARTHUR HL, Diab A, Page DB, Yuan J, et al
    A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling.
    Clin Cancer Res. 2016 Aug 26. pii: clincanres.0190.2016.
    >> Share

  80. BRUFSKY AM, Davidson NE
    Multi-parametric genomic assays for breast cancer: Time for the next generation?
    Clin Cancer Res. 2016 Aug 12. pii: clincanres.1513.2016.
    >> Share

  81. PARSONS HA, Beaver JA, Cimino-Mathews A, Ali SM, et al
    Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple Negative Breast Cancer.
    Clin Cancer Res. 2016 Aug 3. pii: clincanres.1543.2016.
    >> Share

  82. STRULOV SHACHAR S, Deal AM, Weinberg M, Nyrop KA, et al
    Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane Based Chemotherapy.
    Clin Cancer Res. 2016 Aug 3. pii: clincanres.0940.2016.
    >> Share

    July 2016
  83. SAMAEEKIA R, Adorno-Cruz V, Bockhorn J, Chang YF, et al
    MicroRNA-206 inhibits stemness and metastasis of breast cancer by targeting MKL1/IL11 pathway.
    Clin Cancer Res. 2016 Jul 19. pii: clincanres.0943.2016.
    >> Share

  84. AL-AZHRI J, Zhang Y, Bshara W, Zirpoli GR, et al
    Tumor Expression of Vitamin D Receptor and Breast Cancer Histopathological Characteristics and Prognosis.
    Clin Cancer Res. 2016 Jul 12. pii: clincanres.0075.2016.
    >> Share

  85. WALKER AJ, Wedam S, Amiri-Kordestani L, Bloomquist E, et al
    FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
    Clin Cancer Res. 2016 Jul 12. pii: clincanres.0493.2016.
    >> Share

    June 2016
  86. KURLAND BF, Peterson LM, Lee JH, Schubert EK, et al
    Estrogen receptor binding (FES PET) and glycolytic activity (FDG PET) predict progression-free survival on endocrine therapy in patients with ER+ breast cancer.
    Clin Cancer Res. 2016 Jun 24. pii: clincanres.0362.2016.
    >> Share

  87. SHAW JA, Guttery DS, Hills A, Fernandez-Garcia D, et al
    Mutation analysis of cell-free DNA and single circulating tumor cells in metastatic breast cancer patients with high CTC counts.
    Clin Cancer Res. 2016 Jun 22. pii: clincanres.0825.2016.
    >> Share

  88. STOVER DG, Coloff JL, Barry WT, Brugge JS, et al
    The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis.
    Clin Cancer Res. 2016 Jun 21. pii: clincanres.0471.2016.
    >> Share

  89. PATEL H, Abduljabbar R, Lai CF, Periyasamy M, et al
    CDK7, cyclin H and MAT1 is elevated in breast cancer and is prognostic in estrogen receptor- positive breast cancer.
    Clin Cancer Res. 2016 Jun 14. pii: clincanres.1104.2015.
    >> Share

  90. SHARMA P, Lopez-Tarruella S, Garcia-Saenz JA, Ward C, et al
    Efficacy of neoadjuvant carboplatin plus docetaxel in triple negative breast cancer: Combined analysis of two cohorts.
    Clin Cancer Res. 2016 Jun 14. pii: clincanres.0162.2016.
    >> Share

  91. LI W, O'Shaughnessy JA, Hayes DF, Campone M, et al
    Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
    Clin Cancer Res. 2016 Jun 7. pii: clincanres.2452.2015.
    >> Share

  92. WANG ZQ, Milne K, Derocher H, Webb JR, et al
    CD103 and Intratumoral Immune Response in Breast Cancer.
    Clin Cancer Res. 2016 Jun 7. pii: clincanres.0732.2016.
    >> Share

  93. ALVES CL, Elias D, Lyng MB, Bak M, et al
    High CDK6 protects cells from fulvestrant-mediated apoptosis and is a predictor of resistance to fulvestrant in estrogen receptor-positive metastatic breast cancer.
    Clin Cancer Res. 2016 Jun 1. pii: clincanres.1984.2015.
    >> Share

  94. SESTAK I, Zhang Y, Schroeder BE, Schnabel CA, et al
    Cross Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in women with hormone receptor positive lymph-node negative early stage breast cancer.
    Clin Cancer Res. 2016 Jun 1. pii: clincanres.0155.2016.
    >> Share


  95. Correction: Hydroxychloroquine Inhibits Autophagy to Potentiate Antiestrogen Responsiveness in ER+ Breast Cancer.
    Clin Cancer Res. 2016;22:2825.
    >> Share

    May 2016
  96. LYLE LT, Lockman PR, Adkins CE, Mohammad AS, et al
    Alterations in Pericyte Subpopulations are Associated with Elevated Blood-Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer.
    Clin Cancer Res. 2016 May 31. pii: clincanres.1836.2015.
    >> Share

  97. SPEERS C, Zhao SG, Kothari V, Santola A, et al
    Maternal embryonic leucine zipper kinase (MELK) as a novel mediator and biomarker of radioresistance in human breast cancer.
    Clin Cancer Res. 2016 May 25. pii: clincanres.2711.2015.
    >> Share

  98. INGOLD HEPPNER B, Untch M, Denkert C, Pfitzner BM, et al
    Tumor-infiltrating lymphocytes: a predictive and prognostic biomarker in neoadjuvant treated HER2-positive breast cancer.
    Clin Cancer Res. 2016 May 17. pii: clincanres.2338.2015.
    >> Share

  99. JESELSOHN R, Barry WT, Migliaccio I, Biagioni C, et al
    TransCONFIRM: Identification of a genetic signature of response to fulvestrant in advanced hormone receptor positive breast cancer.
    Clin Cancer Res. 2016 May 16. pii: clincanres.0148.2016.
    >> Share

  100. GYANCHANDANI R, Lin Y, Lin HM, Cooper KL, et al
    Intra-tumor heterogeneity affects gene expression profile test prognostic risk stratification in early breast cancer.
    Clin Cancer Res. 2016 May 16. pii: clincanres.2889.2015.
    >> Share

  101. KLINTMAN M, Buus R, Cheang MC, Sheri A, et al
    Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease.
    Clin Cancer Res. 2016;22:2405-16.
    >> Share

  102. DENNISON JB, Shahmoradgoli M, Liu W, Ju Z, et al
    High intra-tumoral stromal content defines Reactive breast cancer as a low-risk breast cancer subtype.
    Clin Cancer Res. 2016 May 12. pii: clincanres.0171.2016.
    >> Share

  103. MITRI Z, Nanda R, Blackwell K, Costelloe CM, et al
    TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis.
    Clin Cancer Res. 2016 May 10. pii: clincanres.2845.2015.
    >> Share

  104. GILANI R, Phadke S, Bao LW, Lachacz E, et al
    UM-164: a potent c-Src/p38 kinase inhibitor with in vivo activity against triple negative breast cancer.
    Clin Cancer Res. 2016 May 6. pii: clincanres.2158.2015.
    >> Share

    February 2016
  105. PODO F, Santoro F, Di Leo G, Manoukian S, et al
    Triple-Negative versus Non-Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRIT-1 MRI-Including Screening Study.
    Clin Cancer Res. 2016;22:895-904.
    >> Share

  106. SAMENI M, Tovar EA, Essenburg CJ, Chalasani A, et al
    Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.
    Clin Cancer Res. 2016;22:923-34.
    >> Share

  107. CHU D, Paoletti C, Gersch C, VanDenBerg DA, et al
    ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients.
    Clin Cancer Res. 2016;22:993-9.
    >> Share

  108. ABDEL-FATAH TM, McArdle SE, Agarwal D, Moseley PM, et al
    HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.
    Clin Cancer Res. 2016;22:905-14.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016